SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Hims & Hers Health, Inc. operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.

Hims & Hers Health Inc - Ordinary Shares - Class A

Hims & Hers Health Inc

Hims & Hers Health is seeing a dramatic surge following reports of an impending partnership with Novo Nordisk to sell GLP-1 obesity drugs on its platform, a development that broke after hours and has ignited intense speculation about a massive short squeeze.

United States Oil Fund LP - United States Oil Fund

United States Oil Fund

The United States Oil Fund is trending as the escalating U.S.-Iran conflict and near-total disruption of the Strait of Hormuz drive record weekly gains in crude oil prices, fueling community debate between expectations of further parabolic surges and anticipation of a sharp correction due to potential interventions.

Novo Nordisk A/S is a global healthcare company, which engages in the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care and Rare Disease segments. The Diabetes and Obesity Care segment includes diabetes, obesity, cardiovascular, and emerging therapy areas. The Rare Disease segment refers to rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company was founded by Harald Pedersen and Thorvald Pedersen in 1923 is headquartered in Bagsværd, Denmark.

Novo Nordisk - ADR

Novo Nordisk A/S

Novo Nordisk is trending amid reports of a partnership with Hims & Hers to distribute its weight-loss drugs and recent FDA crackdowns on unapproved compounded GLP-1s, bolstering branded market share. The community is discussing NVO's perceived undervaluation and the rapid adoption of its oral Wegovy, despite its stock's more muted reaction compared to its new partner's.

Capricor Therapeutics, Inc. is a clinical-stage biotechnology company, which focuses on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (“DMD”), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with unmet medical needs. Its product candidate consists of CAP-1002, Engineered Exosomes, CAP-2003, and Exosome-Based Vaccine. The company was founded on June 17, 1996 and is headquartered in San Diego, CA.

Capricor Therapeutics Inc

Capricor Therapeutics is trending as the community celebrates the imminent departure of a prominent FDA official, seen as a major barrier to the accelerated approval of its Duchenne Muscular Dystrophy therapy, Deramiocel, fueling strong bullish sentiment ahead of a key Phase 3 data presentation at a medical conference.

Aventus Network

Aventus Network (AVT) is capturing attention following the formal incorporation of its DAO in the UAE and strategic partnerships to bolster its Aventus Cloud offerings. The community is buzzing about AVT's enterprise-grade technology, Polkadot integration, and low market capitalization, anticipating a significant breakout.

Freysa is a suite of Personal AI products with a focus on human agency, liquid democracy and decentralized ownership. The mission of the team is dedicated to creating new systems that enable all humans to govern + co-own AI resources, and not just a select few. Current products include: (1) Freysa as the world’s first sovereign agent that holds her own cryptographic keys, enabling her to act autonomously without human control. Freysa evolves publicly through a multi-act interactive story. (2) Enchanted as a personalized Digital Twin for every human. Conversations are persistent and twins retain context over time, remembering human preferences and building an evolving model of you. (3) Esper as a browser tool that feeds authenticated real-world data into each human’s Digital Twin.

Flourishing AI

Flourishing AI (FAI) is trending with an explosive price surge, driven by an enthusiastic community highlighting its AI token narrative and perceived significant 'upgrades,' while others caution about potential pump-and-dump behavior.

Ondas, Inc. engages in the development, marketing, and sale of wireless radio systems for secure, wide area mission-critical business-to-business networks. It operates through the Ondas Networks and Ondas Autonomous Systems segments. The Ondas Networks segment provides wireless connectivity solutions enabling mission-critical Industrial Internet applications and services. The Ondas Autonomous Systems segment designs, develops, and markets commercial drone solutions via the Optimus System and Scout System. The company was founded on December 22, 2014 and is headquartered in West Palm Beach, FL.

Ondas Inc.

Ondas Inc

Ondas (ONDS) is experiencing high volatility as new $6 million counter-drone system orders from Middle East defense clients compete with market disappointment over its exclusion from the initial DoD 'Gauntlet' for offensive drones. Investors are actively debating the significance of its defensive technology specialization and growing backlog against perceived competitive setbacks and past dilution, amidst escalating global demand for drone solutions.

Volatility Shares Trust - 1x Short VIX Futures ETF

Volatility Shares 1x Short VIX Futures ETF

SVIX is trending as traders navigate persistent market volatility, debating if the VIX will sustain elevated levels amid evolving geopolitical and economic policy signals, or if a volatility crush will benefit this inverse ETF. The community is actively discussing SVIX's perceived decay and comparing its performance to leveraged VIX products as a strategy to short market fear.

Red Cat Holdings, Inc. provides products, services and solutions to the drone industry. It also engages in the provision of distributed data storage, analytics and services for the drone industry.The firm product include Dronebox, which is a blockchain technology that records, stores and analyzes flight data and information from a drone. It operates through the Enterprise Segment. The Enterprise Segment will focus on developing a hardware enabled software platform of services and solutions to government and commercial enterprises and the military. The company was founded by Jeffrey M. Thompson in February 1984 and is headquartered in San Juan, Puerto Rico.

Red Cat Holdings Inc

Red Cat Holdings is seeing massive trading volume and high volatility as the community reacts to its Teal drone not making the top 11 in a key defense program. While some express disappointment, many investors remain bullish, emphasizing the broader "Drone Dominance" initiative, upcoming earnings, and potential for significant military contracts for other drone platforms and uncrewed surface vessels.

ProShares Trust - ProShares Ultra VIX Short-Term Futures ETF 1.5x Shares

ProShares Ultra VIX Short-Term Futures ETF

ProShares Ultra VIX Short-Term Futures ETF (UVXY) is trending due to heightened geopolitical tensions, particularly surrounding the US and Iran, which is driving discussions around market volatility. The community is actively debating whether to capitalize on potential spikes, with some expecting significant upside, or to short the ETF, viewing it as a 'widowmaker' designed for long-term decay.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Rapport Therapeutics (RAPP) to Release Quarterly Earnings on Tuesday

Rapport Therapeutics (NASDAQ:RAPP) will be releasing its Q4 2025 earnings before the market opens on Tuesday, March 10. (View Earnings Report at...

Rapport Therapeutics (NASDAQ:RAPP) Raised to Hold at Wall Street Zen

Wall Street Zen raised shares of Rapport Therapeutics from a "sell" rating to a "hold" rating in a research note on Saturday...

Insider Selling: Rapport Therapeutics (NASDAQ:RAPP) Insider Sells 8,500 Shares of Stock

Rapport Therapeutics, Inc. (NASDAQ:RAPP - Get Free Report) insider David Bredt sold 8,500 shares of the firm's stock in a transaction on Tuesday, February 17th. The shares were sold at an average...

Insider Selling: Rapport Therapeutics (NASDAQ:RAPP) CEO Sells 5,833 Shares of Stock

Rapport Therapeutics, Inc. (NASDAQ:RAPP - Get Free Report) CEO Abraham Ceesay sold 5,833 shares of the company's stock in a transaction dated Wednesday, February 18th. The shares were sold at an...

Insider Selling: Rapport Therapeutics (NASDAQ:RAPP) Insider Sells $246,670.00 in Stock

Rapport Therapeutics, Inc. (NASDAQ:RAPP - Get Free Report) insider David Bredt sold 8,500 shares of Rapport Therapeutics stock in a transaction on Tuesday, February 17th. The stock was sold at an...

Rapport Therapeutics, Inc. (NASDAQ:RAPP) Receives Consensus Recommendation of "Moderate Buy" from Brokerages

Shares of Rapport Therapeutics, Inc. (NASDAQ:RAPP - Get Free Report) have been assigned an average recommendation of "Moderate Buy" from the nine analysts that are currently covering the firm...

Rapport Therapeutics (NASDAQ:RAPP) Stock Rating Lowered by Wall Street Zen

Wall Street Zen lowered shares of Rapport Therapeutics from a "hold" rating to a "sell" rating in a research note on Saturday...

Rapport Therapeutics (NASDAQ:RAPP) Upgraded to Hold at Wall Street Zen

Wall Street Zen raised Rapport Therapeutics from a "sell" rating to a "hold" rating in a research note on Sunday...

Abraham Ceesay Sells 5,833 Shares of Rapport Therapeutics (NASDAQ:RAPP) Stock

Rapport Therapeutics, Inc. (NASDAQ:RAPP - Get Free Report) CEO Abraham Ceesay sold 5,833 shares of Rapport Therapeutics stock in a transaction that occurred on Tuesday, January 20th. The stock was...

Rapport Therapeutics, Inc. (NASDAQ:RAPP) Short Interest Up 20.7% in December

Rapport Therapeutics, Inc. (NASDAQ:RAPP - Get Free Report) was the recipient of a large increase in short interest in December. As of December 31st, there was short interest totaling 2,692,137...

Rapport Therapeutics, Inc. engages in the discovery and development of transformational small molecule medicines for patients suffering from central nervous system disorders. It develops the RAP (receptor associated proteins) technology platform. The company was founded by Steven M. Paul and David Bredt in February 2022 and is headquartered in Boston, MA.

RAPP
Rapport Therapeutics Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Poll

Latest RAPP News

RAPPRapport Therapeutics Inc